Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I, Kleijn A, Ju J, Jimenez-Cowell K, Fabro F, Klein M, Chi Yen RT, Balvers RK, Li Y, Stubbs AP, Kers TV, Kros JM, Lawler SE, Beerepoot LV, Kremer A, Idbaih A, Verreault M, Byrne AT, O'Farrell AC, Connor K, Biswas A, Salvucci M, Prehn JHM, Lambrechts D, Dilcan G, Lodi F, Arijs I, van den Bent MJ, Dirven CMF, Leenstra S; GLIOTRAIN consortium; Lamfers MLM. Ntafoulis I, et al. Among authors: van den bent mj. Br J Cancer. 2023 Oct;129(8):1327-1338. doi: 10.1038/s41416-023-02402-y. Epub 2023 Aug 24. Br J Cancer. 2023. PMID: 37620410 Free PMC article.
Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.
van den Bent MJ, Schellens JH, Vecht CJ, Sillevis Smit PA, Loosveld OJ, Ma J, Tijssen CC, Jansen RL, Kros JM, Verweij J. van den Bent MJ, et al. Eur J Cancer. 1998 Sep;34(10):1570-4. doi: 10.1016/s0959-8049(98)00138-5. Eur J Cancer. 1998. PMID: 9893630 Clinical Trial.
Temozolomide chemotherapy in recurrent oligodendroglioma.
van den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, Carpentier AF. van den Bent MJ, et al. Neurology. 2001 Jul 24;57(2):340-2. doi: 10.1212/wnl.57.2.340. Neurology. 2001. PMID: 11468326
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, Kros JM, Stege EB, Enting RH, Allgeier A, van Heuvel I, van den Bent MJ. Triebels VH, et al. Among authors: van heuvel i, van den bent mj. Neurology. 2004 Sep 14;63(5):904-6. doi: 10.1212/01.wnl.0000137049.65631.db. Neurology. 2004. PMID: 15365146 Clinical Trial.
Low-molecular weight caldesmon as a potential serum marker for glioma.
Zheng PP, Hop WC, Sillevis Smitt PA, van den Bent MJ, Avezaat CJ, Luider TM, Kros JM. Zheng PP, et al. Among authors: van den bent mj. Clin Cancer Res. 2005 Jun 15;11(12):4388-92. doi: 10.1158/1078-0432.CCR-04-2512. Clin Cancer Res. 2005. PMID: 15958622
[Favourable result for temozolomide in recurrent high-grade glioma].
Taal W, van der Rijt CD, Sillevis Smitt PA, Kros JM, van Heuvel I, Enting RH, van den Bent MJ. Taal W, et al. Among authors: van heuvel i, van der rijt cd, van den bent mj. Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1393-9. Ned Tijdschr Geneeskd. 2005. PMID: 15997692 Dutch.
409 results